FGEN Key Statistics, Chart & Performance
The current stock price of FGEN is 8.6 USD. In the past month the price increased by 3.61%. In the past year, price decreased by -14%.
FGEN Latest News, Press Relases and Analysis
FGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24 | 400.88B | ||
| AMGN | AMGEN INC | 14.97 | 176.29B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.28 | 115.75B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.76 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.29B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.44 | 25.64B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.6 | 22.27B | ||
| INCY | INCYTE CORP | 16 | 20.16B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.32B |
Related stock screener links
About FGEN
Company Profile
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2014-11-14. The company is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. The company is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
Company Info
FIBROGEN INC
350 Bay Street, Suite 100 #6009
San Francisco CALIFORNIA 94158 US
CEO: Enrique Conterno
Employees: 225
Phone: 14159781200
FIBROGEN INC / FGEN FAQ
What does FIBROGEN INC do?
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2014-11-14. The company is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. The company is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
Can you provide the latest stock price for FIBROGEN INC?
The current stock price of FGEN is 8.6 USD. The price increased by 3.37% in the last trading session.
Does FGEN stock pay dividends?
FGEN does not pay a dividend.
What is the ChartMill technical and fundamental rating of FGEN stock?
FGEN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for FGEN stock?
The Revenue of FIBROGEN INC (FGEN) is expected to decline by -96.23% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is FIBROGEN INC worth?
FIBROGEN INC (FGEN) has a market capitalization of 34.83M USD. This makes FGEN a Nano Cap stock.
Who owns FIBROGEN INC?
You can find the ownership structure of FIBROGEN INC (FGEN) on the Ownership tab.
FGEN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FGEN. When comparing the yearly performance of all stocks, FGEN is a bad performer in the overall market: 83.97% of all stocks are doing better.
FGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FGEN. FGEN has a bad profitability rating. Also its financial health evaluation is rather negative.
FGEN Financial Highlights
Over the last trailing twelve months FGEN reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS increased by 102.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2598.87% | ||
| ROA | 157.4% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FGEN Forecast & Estimates
8 analysts have analysed FGEN and the average price target is 43.86 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 8.6.
For the next year, analysts expect an EPS growth of 52.49% and a revenue growth -96.23% for FGEN